Bayer (ETR:BAYN) Stock Upgrade
The stock rating of Bayer (ETR:BAYN) shares was lifted by research professionals at Bankhaus Lampe KG to a respectable “Buy”. They currently have a Estimated Target Price of EUR 149.00 on BAYN. Bankhaus Lampe KG’s Estimated Target Price may mean a possible upside of 20.36% from the closing share price of the company.
From a total of 17 analysts covering Bayer (ETR:BAYN) stock, 8 rate it a ”Buy”, 0 a “Sell”, and 9 a ”Hold”. This means that 47% of the ratings are positive. The highest target price is €160 while the lowest target price is €121. The mean of all analyst targets is €142.03 with a 14.68% above today’s (€123.85) stock price. Bayer was the topic of 50 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank upgraded shares on December 1 to “Buy” rating. Landesbank maintained shares with “Hold” rating and €125 target share price in a report from an October 31. Credit Suisse upgraded BAYN stock in a recent report from November 17 to “Outperform” rating. Independent Research upgraded the rating on October 31. Independent Research has a “Buy” rating and a €148 price target on shares. Finally, Commerzbank maintained the stock with “Hold” rating in a report issued on a November 7.
The stock decreased 0.80% or EUR 1 on December 2, striking EUR 123.85. Approximately 1.54M shares of stock traded hands. Bayer AG (ETR:BAYN) has 0.00% since May 6, 2015 and is . It has outperformed by 0.20% the S&P500.
Bayer AG is a strategic management holding company. The company has a market cap of 102.42 billion EUR. The Company’s business are organized into three subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. It has 28.11 P/E ratio. Bayer HealthCare researches, develops, makes and markets products to improve the health of people and animals.